[go: up one dir, main page]

MX2016012691A - Nuevos compuestos de succinato permeables a la celula. - Google Patents

Nuevos compuestos de succinato permeables a la celula.

Info

Publication number
MX2016012691A
MX2016012691A MX2016012691A MX2016012691A MX2016012691A MX 2016012691 A MX2016012691 A MX 2016012691A MX 2016012691 A MX2016012691 A MX 2016012691A MX 2016012691 A MX2016012691 A MX 2016012691A MX 2016012691 A MX2016012691 A MX 2016012691A
Authority
MX
Mexico
Prior art keywords
cell
new
succinate
atp
permeable
Prior art date
Application number
MX2016012691A
Other languages
English (en)
Other versions
MX378072B (es
Inventor
Elmer Eskil
Joakim Hansson Magnus
Henrik Johannes Ehinger Karl
Moss Steven
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58804197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016012691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MX2016012691A publication Critical patent/MX2016012691A/es
Publication of MX378072B publication Critical patent/MX378072B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/18—Eight-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se refiere a nuevos succinatos permeables a la célula y precursores de succinato permeables a la célula dirigidos para incrementar la producción de ATP en la mitocondria. La parte principal de ATP producida y utilizada en la célula eucariótica se origina de la fosforilación oxidativa mitocondrial, un proceso al cual se proporcionan electrones de alta energía por el ciclo de Krebs. No todos los intermediarios del ciclo de Krebs son fácilmente permeables a la membrana celular, uno de ellos es succinato. La provisión de nuevos succinatos permeables a la célula se contempla para permitir el pasaje sobre la membrana celular y de este modo los succinatos permeables a la célula pueden ser usados para mejorar el rendimiento de ATP mitocondrial.
MX2016012691A 2014-04-08 2015-04-08 Nuevos compuestos de succinato permeables a la celula. MX378072B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470190 2014-04-08
PCT/EP2015/057606 WO2015155231A1 (en) 2014-04-08 2015-04-08 Novel cell-permeable succinate compounds

Publications (2)

Publication Number Publication Date
MX2016012691A true MX2016012691A (es) 2016-12-16
MX378072B MX378072B (es) 2025-03-10

Family

ID=58804197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012691A MX378072B (es) 2014-04-08 2015-04-08 Nuevos compuestos de succinato permeables a la celula.

Country Status (25)

Country Link
US (2) US11147789B2 (es)
EP (2) EP3391941B1 (es)
JP (4) JP7082861B6 (es)
KR (1) KR102322543B1 (es)
CN (1) CN106458957B (es)
AU (2) AU2015243346C9 (es)
CA (1) CA2944565C (es)
CY (1) CY1120650T1 (es)
DK (1) DK3129016T3 (es)
EA (1) EA035678B1 (es)
ES (2) ES2683860T3 (es)
HR (1) HRP20181126T1 (es)
IL (1) IL247904B (es)
LT (2) LT3129016T (es)
MA (2) MA44092B1 (es)
MX (1) MX378072B (es)
PL (1) PL3129016T3 (es)
PT (2) PT3391941T (es)
RS (1) RS57624B1 (es)
SG (1) SG11201607907PA (es)
SI (1) SI3129016T1 (es)
SM (1) SMT201800429T1 (es)
TR (1) TR201810411T4 (es)
WO (1) WO2015155231A1 (es)
ZA (1) ZA201606608B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944565C (en) * 2014-04-08 2022-11-29 Neurovive Pharmaceutical Ab Novel cell-permeable succinate compounds
SG11201607908QA (en) 2014-04-08 2016-10-28 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
CN106458839A (zh) * 2014-04-08 2017-02-22 纽维制药有限公司 用于增加atp生产的琥珀酸的前药
WO2017060422A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders
WO2017060418A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
WO2017060400A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
WO2017096270A1 (en) * 2015-12-03 2017-06-08 The Regents Of The University Of California Methods for treating mitochondrial diseases
CN112888419A (zh) * 2018-10-11 2021-06-01 安布里亚制药公司 用于治疗和预防Leber遗传性视神经病变的组合物和方法
US20210346329A1 (en) * 2018-10-11 2021-11-11 Imbria Pharmaceuticals, Inc. Tca cycle intermediates and methods of use thereof
CN109675037B (zh) * 2019-01-25 2021-09-14 南方医科大学 Atp及其受体在制备治疗自闭症药物中的应用
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756422A (en) * 1950-09-14 1956-09-05 Saint Gobain Esters of urethanes of glycols and the manufacture thereof
NL6806584A (es) * 1965-09-20 1968-11-12
FR2265355B1 (es) * 1974-03-28 1977-11-04 Blum Jean
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
DE4101158C2 (de) 1991-01-14 1994-06-23 Dainippon Ink & Chemicals Wärmehärtbare Reaktionsharzgemische, Verwendung der erfindungsgemäßen Reaktionsharze zur Herstellung von Formkörpern und Beschichtungen
EP0583480A4 (en) 1992-02-07 1994-03-18 Tsumura & Co Side-effect alleviant.
JPH07331262A (ja) 1994-05-31 1995-12-19 Tonen Corp パティキュレート低減用添加剤及び該添加剤を用いたディーゼルエンジン用燃料組成物
CN1222139A (zh) * 1996-06-13 1999-07-07 里奥药物制品有限公司 多元醇琥珀酸酯及其药物制剂
GB9612331D0 (en) * 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AU765821B2 (en) * 1998-07-02 2003-10-02 Board Of Regents Of The Leland Stanford Junior University, The Methods for making polyketides
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
EP1401850A1 (en) * 2001-06-20 2004-03-31 Nuevolution A/S Nucleoside derivatives for library preparation
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR100791844B1 (ko) 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
US20120308646A1 (en) * 2007-01-18 2012-12-06 Hesheng Zhang Tetracyclic anthraquinones possessing anti-cancer properties
BRPI0809423A2 (pt) 2007-03-26 2014-09-09 Salutria Pharmaceuticals Llc Usos e composições de derivados de probucol para o tratamento de diabetes
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
JP2014024772A (ja) 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
ES2661009T3 (es) 2012-10-05 2018-03-27 Neurovive Pharmaceutical Ab Succinatos protegidos para mejorar la producción de ATP mitocondrial
SG11201607908QA (en) 2014-04-08 2016-10-28 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
CA2944565C (en) * 2014-04-08 2022-11-29 Neurovive Pharmaceutical Ab Novel cell-permeable succinate compounds
CN106458839A (zh) 2014-04-08 2017-02-22 纽维制药有限公司 用于增加atp生产的琥珀酸的前药

Also Published As

Publication number Publication date
JP7082861B2 (ja) 2022-06-09
RS57624B1 (sr) 2018-11-30
MA39855B1 (fr) 2018-10-31
JP2021169519A (ja) 2021-10-28
SI3129016T1 (sl) 2018-10-30
BR112016023086A8 (pt) 2021-06-29
HRP20181126T1 (hr) 2018-10-05
US12310940B2 (en) 2025-05-27
SMT201800429T1 (it) 2018-09-13
ZA201606608B (en) 2022-10-26
BR112016023086A2 (pt) 2017-08-15
MA44092B1 (fr) 2023-08-31
HK1255109A1 (en) 2019-08-02
MA39855A (fr) 2018-10-24
PT3391941T (pt) 2023-08-24
AU2018282308B2 (en) 2020-04-30
TR201810411T4 (tr) 2018-08-27
US20210401792A1 (en) 2021-12-30
CY1120650T1 (el) 2019-12-11
ES2683860T3 (es) 2018-09-28
EA035678B1 (ru) 2020-07-24
JP2020100628A (ja) 2020-07-02
AU2015243346C9 (en) 2019-03-07
CA2944565A1 (en) 2015-10-15
AU2015243346A1 (en) 2016-10-13
ES2953522T3 (es) 2023-11-14
PT3129016T (pt) 2018-10-01
JP7229189B2 (ja) 2023-02-27
AU2015243346B2 (en) 2018-10-18
KR102322543B1 (ko) 2021-11-04
KR20160142861A (ko) 2016-12-13
JP2017513829A (ja) 2017-06-01
SG11201607907PA (en) 2016-10-28
EP3129016A1 (en) 2017-02-15
JP7082861B6 (ja) 2023-12-22
EA201692017A1 (ru) 2017-02-28
LT3129016T (lt) 2018-09-10
EP3129016B1 (en) 2018-06-06
PL3129016T3 (pl) 2018-10-31
AU2018282308A1 (en) 2019-01-17
US20170105961A1 (en) 2017-04-20
CN106458957A (zh) 2017-02-22
CN106458957B (zh) 2020-08-18
EP3391941B1 (en) 2023-06-07
US11147789B2 (en) 2021-10-19
EP3391941A1 (en) 2018-10-24
IL247904A0 (en) 2016-11-30
DK3129016T3 (en) 2018-09-03
JP2021169518A (ja) 2021-10-28
IL247904B (en) 2020-08-31
CA2944565C (en) 2022-11-29
AU2015243346C1 (en) 2019-02-07
LT3391941T (lt) 2023-11-10
MX378072B (es) 2025-03-10
WO2015155231A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
MX2016012691A (es) Nuevos compuestos de succinato permeables a la celula.
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CO2019003178A2 (es) Compuestos de dinucleótidos cíclicos
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
EA201692018A1 (ru) Пролекарства янтарной кислоты для повышения производства atp
CO2018013141A2 (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2019001437A (es) Composicion de polipropileno con actividad retardante de flama.
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
ECSP16088985A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
MX374828B (es) Composiciones y metodos para alterar la señalizacion del segundo mensajero.
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
MX2015011529A (es) Reordenamiento del virus de infuenza b.
MX2018004910A (es) Composicion de polipropileno para un elemento de capa.
MX2015014991A (es) Aparato de filtro electroquimico.
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
CL2017001938A1 (es) Proceso para la fabricación de una solución de un hidrógenocarbonato alcalinotérreo
MX2017012021A (es) Compuestos antifungicos y procesos para la fabricacion.
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
CL2018003028A1 (es) Loci genéticos asociados con una mayor fertilidad en el maíz (divisional de la solicitud n° 2071-2016).
DOP2015000187A (es) Proceso de fabricación de vortioxetina
CR20170005A (es) Derivados de insoindolina
MX2016015092A (es) Inhibidor de proliferacion de celulas madre cancerosas.
MX392637B (es) Composiciones para el cuidado de telas que comprenden polimeros de poliuretano, poliurea y/o poliuretanourea.
MX358291B (es) Cauchos de nitrilo de color estable.
AR098731A1 (es) Artículo absorbente con múltiples sustratos